A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ

Table 1

Baseline clinical and histopathological characteristics among women with a primary DC44IS who later developed either an invasive cancer or an in situ recurrence. Women with a known recurrence were recruited from two source populations: a population based cohort (U/V cohort, 𝑛=458) and a randomized study (SweDCIS, 𝑛=1,046).

Baseline characteristics at; diagnosis of primary DCIS	All DCIS with a recurrence (𝑛=266)
	U/V cohort (𝑛=100); Type of recurrence		SweDCIS (𝑛=166); Type of recurrence		All DCIS with a recurrence (𝑛=266); Type of recurrence
	Invasive (𝑛=55)	In situ (𝑛=45)	Invasive (𝑛=81)	In situ (𝑛=85)	Invasive (𝑛=136)	In situ (𝑛=130)
	Number	Number	Number	Number	Number (%)	Number (%)
Time to recurrence, months (mean ± SD)	65±44	54±49	67±43	37±27	67±44	44±37
Age at diagnose (𝑛=266)
≤45	9	7	16	14	25 (18.4)	21 (16.2)
46–60	22	22	36	39	58 (42.7)	61 (46.9)
>60	24	16	29	32	53 (38.9)	48 (36.9)
Mode of detection (𝑛=265)
Screening	37	36	53	65	90 (66.7)	101 (77.7)
Clinically	18	9	27	20	45 (33.3)	29 (22.3)
Tumor size (𝑛=234)
≤15 mm	34	16	40	41	74 (63.2)	57 (48.7)
>15 mm or multifocal	17	24	26	36	43 (36.8)	60 (51.3)
Type of surgery (𝑛=266)
Breast conserving surgery	50	41	81	85	131 (96.3)	126 (96.9)
Mastectomy	5	4	—	—	5 (3.7)	4 (3.1)
Postoperative radiotherapy (𝑛=266)
Yes	14	12	27	20	41 (30.2)	32 (24.6)
No	41	33	54	65	95 (69.8)	98 (75.4)
Free margins (𝑛=255)
Yes	47	34	61	65	108 (80.0)	99 (76.2)
No or doubtful	8	11	19	20	27 (20.0)	31 (23.9)
Nuclear grade (𝑛=241)
I	5	6	6	1	11 (9.2)	7 (5.8)
II	19	17	26	21	45 (37.5)	38 (31.4)
III	26	21	38	55	64 (53.3)	76 (62.8)